Modality
Radioligand
MOA
CDK2i
Target
GLP-1R
Pathway
PI3K/AKT
Bladder Ca
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
~Sep 2018
→ ~Dec 2019
Phase 3
~Mar 2020
→ ~Jun 2021
NDA/BLA
~Sep 2021
→ ~Dec 2022
Approved
Mar 2023
→ Dec 2031
ApprovedCurrent
NCT07433083
1,609 pts·Bladder Ca
2023-03→2031-12·Terminated
1,609 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-12-035.7y awayPh3 Readout· Bladder Ca
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Termina…
Catalysts
Ph3 Readout
2031-12-03 · 5.7y away
Bladder Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07433083 | Approved | Bladder Ca | Terminated | 1609 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R |